Accro Bioscience
Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease.
$50MSeries C
Role not disclosedCC
Cenova Capital
Activity from announced rounds
Activity in this selectionnrw-venture-f5757e51
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $50M 1 disclosed · full round size, not this investor’s share